Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

NOTE: These posts are picked from multiple sources please visit the link below to check full details.


(adsbygoogle = window.adsbygoogle || []).push({});

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia submitted by /u/indolgofera
[link] [comments]

source
Please select the source link above

Be the first to comment

Leave a Reply

Your email address will not be published.


*